HEALTH● LOWJul 28 · Jul 28, 2026, 11:29 AM
Altimmune rises as GLP-1 cuts drinking in mid-stage trial
Seeking Alpha Tech
Altimmune's stock increased following positive mid-stage trial results for its GLP-1 drug, which reportedly reduced drinking. This indicates potential progress in a new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH1h agoEli Lilly reports promising lung cancer drug resultsSeeking Alpha TechHEALTH1h agoUkraine receives over 230,000 doses of inactivated polio vaccineUkrinform [en]HEALTH2h agoRoche lung cancer drug extends survival by nearly six months in late-stage trialSeeking Alpha TechHEALTH2h agoJohnson & Johnson reports response rate for head, neck cancer treatmentSeeking Alpha Tech